For patients prescribed RYBREVANT® in combination with LAZCLUZE™
Connect 1-on-1 with a Care Navigator to explore cost support, education, and resources for emotional support needs by calling 833-JNJ-WME1 (833-565-9631).
Now available as a first treatment for advanced non–small cell lung cancer with common EGFR mutations (exon 19 deletions or exon 21 L858R substitution)
Contact your doctor right away if you experience any serious side effects.
Connect 1-on-1 with a Care Navigator to explore cost support, education, and resources for emotional support needs by calling 833-JNJ-WME1 (833-565-9631).
The only therapy designed to target advanced non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations as first treatment for adults in combination with chemotherapy.
RYBREVANT® in combination with carboplatin and pemetrexed (chemotherapy) extended the time people lived without cancer growing or spreading
Almost twice the time without disease progression.
At 11.4 months, half of the people treated with RYBREVANT® + chemotherapy lived without the disease getting worse, compared to 6.7 months for chemotherapy alone.
RYBREVANT® in combination with carboplatin and pemetrexed (chemotherapy) extended the time people lived without cancer growing or spreading
Almost twice the time without disease progression.
At 11.4 months, half of the people treated with RYBREVANT® + chemotherapy lived without the disease getting worse, compared to 6.7 months for chemotherapy alone.
